GSK plc vs Utilities Select Sector SPDR Fund — how do they compare? GSK plc trades at $50.38 (market cap $102.60B), while Utilities Select Sector SPDR Fund trades at $43.81. The key difference: GSK plc pays a 3.57% dividend while Utilities Select Sector SPDR Fund pays none, and GSK plc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| GSK | XLU | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | — |
52-Week High | $61.18 | $47.73 |
52-Week Low | $38.22 | $41.31 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
XLU, the Utilities Select Sector SPDR Fund, trades at $43.76, up 1.44% today but showing a bearish technical trend with 14 sell signals. The ETF benefits from AI-driven power demand, positioning utilities as growth plays amid easing rates. Recent news highlights unusual call option volume and a dividend scheduled for June 2026, reflecting defensive income appeal.
Outlook is mixed: AI power needs offer growth, but technical weakness and regulatory risks weigh. Investors gain exposure to stable dividends and infrastructure demand, yet face volatility from interest rates and grid capacity constraints. The stock's bearish signals suggest cautious entry points.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →